The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis

Gleb Slobodin; Itzhak Rosner; Doron Rimar; Nina Boulman; Michael Rozenbaum; Majed Odeh

doi:10.1007/s10067-010-1378-6

The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis

Clin Rheumatol. 2010 Jul;29(7):793-4. doi: 10.1007/s10067-010-1378-6. Epub 2010 Jan 29.

Authors

Gleb Slobodin¹, Itzhak Rosner, Doron Rimar, Nina Boulman, Michael Rozenbaum, Majed Odeh

Affiliation

¹ Department of Internal Medicine A, Bnai Zion Medical Center, Ruth & Bruce Rappaport Faculty of Medicine, Technion, Haifa, 31048, PO Box 4940, Israel. gslobodin@yahoo.com

PMID: 20111975
DOI: 10.1007/s10067-010-1378-6

Abstract

A patient with ankylosing spondylitis, after demonstrating incomplete clinical response to adalimumab, received three monthly infusions of pamidronate along with continuing TNF-alpha blockade. Complete disappearance of the back pain was reported after the second pamidronate infusion. The perspectives of the combination therapy with TNF-alpha inhibitor and pamidronate are discussed.

Publication types

Case Reports

MeSH terms

Adalimumab
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Diphosphonates / therapeutic use*
Drug Synergism
Drug Therapy, Combination
Female
Humans
Middle Aged
Pamidronate
Spondylitis, Ankylosing / drug therapy*
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Diphosphonates
Adalimumab
Pamidronate